FDMT — 4D Molecular Therapeutics, Inc. stock price, charts and financials

Latest market price

10.26

+0.17+1.68%

Overview Short InterestFilings

FDMTQT584D Molecular Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

10.26+1.68%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-2.48	Insider Own	35.91%	Shs Outstand	52.28M	Perf Week	4.16%

Market Cap	536.35M	Forward P/E	-	EPS next Y	-4.11	Insider Trans	-1.09%	Shs Float	39.01M	Perf Month	-19.34%

Enterprise Value	160.35M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	29.13%	Perf Quarter	8.69%

Income	-140.00M	P/S	6.31	EPS this Y	-63.58%	Inst Trans	-	Short Ratio	13.28	Perf Half Y	12.13%

Sales	85.00M	P/B	1.19	EPS next Y	-1.41%	ROA	-31.37%	Short Interest	11.36M	Perf YTD	36.80%

Book/sh	8.65	P/C	1.37	EPS next 5Y	-	ROE	-36.83%	52W High	14.00 -26.71%	Perf Year	59.81%

Cash/sh	7.48	P/FCF	-	EPS past 3/5Y	-	ROIC	-37.80%	52W Low	5.11 100.78%	Perf 3Y	-44.06%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	204.86% 43.44%	Gross Margin	-12.45%	Volatility	5.83% 6.53%	Perf 5Y	-57.34%

Dividend TTM	-	EV/Sales	1.89	EPS Y/Y TTM	13.76%	Oper. Margin	-203.47%	ATR (14)	0.74	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	9.34	Sales Y/Y TTM	-	Profit Margin	-182.34%	RSI (14)	45.03	Recom	2.36

Dividend Gr. 3/5Y	-	Current Ratio	9.34	EPS Q/Q	-17.44%	SMA20	-6.32%	Beta	2.65	Target Price	33.00

Payout	0.00%	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-2.59%	Rel Volume	0.56	Prev Close	10.09

Employees	196	LT Debt/Eq	0.03	Earnings	Aug 10	SMA200	5.01%	Avg Volume	851.07K	Price	10.26

IPO Date	Dec 11, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.45% 17.76%	Net Debt/EBITDA	0.32	Volume	478,301	Change	1.68%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-08-26	Reiterated	Goldman Sachs	Buy	$38 → $33
Nov-11-25	Reiterated	Barclays	Overweight	$33
Oct-31-25	Reiterated	Leerink Partners	Outperform	$17
Oct-21-25	Reiterated	RBC Capital	Outperform	$40 → $26
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-19-24	Reiterated	BMO Capital	Outperform	$40
Sep-19-24	Reiterated	Loop Capital Markets		$39
Apr-15-24	Reiterated	Barclays
Apr-15-24	Reiterated	RBC Capital	Outperform	$40
Apr-01-24	Reiterated	Jefferies	Buy

Latest News

Jul-31-26

Jul-31-2611:52AM

B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price Target of $37Benzinga

Jul-29-26

Jul-29-2603:22PM

10 Stock Picks to Celebrate 45 Years of Schaeffer'sschaeffersresearch.com

Jul-20-26

Jul-20-2602:16PM

4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion OpportunitySeekingAlpha

Jul-18-26

Jul-18-2603:15PM

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Populationglobenewswire.com

Jul-17-26

Jul-17-2604:05PM

4DMT Announces New Employment Inducement Grantsglobenewswire.com

Jun-30-26

Jun-30-2604:05PM

4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialistsglobenewswire.com

Jun-29-26

Jun-29-2608:02AM

4D Molecular Therapeutics Completes Enrollment For Its 4FRONT-2 Second Phase 3 Clinical Trial Evaluating 4D-150 In Patients With Wet Age-Related Macular DegenerationBenzinga

08:00AM

4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMDglobenewswire.com

08:00AM

4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capitalglobenewswire.com

Company

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	85	0	21	3	18	14	7	14	6
Cost of Goods Sold Incl. D&A	8	141	97	80	61	53	39	18	14
Gross Profit	78	-141	-76	-77	-43	-39	-32	-4	-8
Selling, General and Administrative Excl. Other	49	47	36	33	28	17	14	6	3
Research and Development	196	141	97	80	61	53	44	18	14
Other Operating Expense	-8	-141	-97	-80	-61	-53	-39	1	0
Operating Income	-160	-188	-113	-110	-71	-57	-51	-10	-11
Interest Expense	0	0	0	0	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	19	27	12	3	0	0	1	1	0
Net Income Before Taxes	-140	-161	-101	-107	-71	-57	-49	-10	-11
Income Taxes	0	0	0	0	0	0	0	0	0
Consolidated Net Income	-140	-161	-101	-107	-71	-57	-49	-10	-11
Net Income From Continuing Operations	-140	-161	-101	-107	-71	-57	-49	-10	-11
Net Income	-140	-161	-101	-107	-71	-57	-49	-10	-11
EPS (Recurring)	-2.42	-2.98	-2.58	-3.12	-2.46	-2.12	-2.00	-0.76	-0.76
EPS (Basic, Before Extraordinaries)	-2.42	-2.98	-2.58	-3.12	-2.46	-2.12	-2.00	-0.76	-0.76
EPS (Diluted)	-2.42	-2.98	-2.58	-3.12	-2.46	-2.12	-2.00	-0.76	-0.76
EBITDA	-132	-154	-97	-105	-70	-55	-45	-10	-11
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	5.12	—	37.63	236.91	34.13	79.94	—	—	—
Gross Margin	91.76	—	-361.90	-2,566.67	-238.89	-278.57	-457.14	-28.57	-133.33
Operating Margin	-188.24	—	-538.10	-3,666.67	-394.44	-407.14	-728.57	-71.43	-183.33
Net Margin	-164.71	—	-480.95	-3,566.67	-394.44	-407.14	-700.00	-71.43	-183.33
Shares Outstanding	58	54	39	32	28	27	26	13	15
Market Capitalization	435	301	790	711	614	1,119	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kirn David	See Remarks	Aug 03 '26	Sale	10.05	12,415	124,722	871,737	Aug 04
Kirn David	See Remarks	Jul 10 '26	Sale	12.03	15,725	189,233	884,152	Jul 14
Kirn David	See Remarks	Jul 09 '26	Sale	12.87	42,608	548,177	899,877	Jul 14
Bizily Scott	Chief Legal Officer	Jun 30 '26	Option Exercise	6.20	6,566	40,700	15,183	Jul 02
Bizily Scott	Chief Legal Officer	Jun 30 '26	Sale	14.00	6,566	91,924	8,617	Jul 02
Bizily Scott	Chief Legal Officer	Jun 23 '26	Option Exercise	4.14	9,810	40,613	18,427	Jun 25
Bizily Scott	Chief Legal Officer	Jun 23 '26	Sale	12.00	9,810	117,720	8,617	Jun 25
Kirn David	See Remarks	Jun 22 '26	Sale	10.47	114,746	1,200,851	942,485	Jun 23
Kirn David	See Remarks	Jun 01 '26	Sale	10.02	1,922	19,258	1,057,231	Jun 02
Gupta Ashoo	VP, Finance and Controller	Mar 20 '26	Option Exercise	0.00	1,086	0	47,224	Mar 24
Gupta Ashoo	VP, Finance and Controller	Mar 20 '26	Sale	8.61	390	3,358	46,914	Mar 24
Gupta Ashoo	VP, Finance and Controller	Dec 20 '25	Option Exercise	0.00	1,086	0	46,528	Dec 23
Gupta Ashoo	VP, Finance and Controller	Dec 20 '25	Sale	8.68	389	3,377	46,218	Dec 23
Bizily Scott	Chief Legal Officer	Dec 16 '25	Option Exercise	4.14	1,635	6,769	5,229	Dec 19
Bizily Scott	Chief Legal Officer	Dec 16 '25	Sale	10.90	1,635	17,822	3,594	Dec 19

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.